A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects With Treatment-Resistant Depression
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs TAK 653 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 06 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 25 Jan 2018 Planned initiation date changed from 15 Nov 2017 to 15 Feb 2018.
- 22 Oct 2017 New trial record